Low-dose rosuvastatin/ezetimibe comparable to high-dose rosuvastatin

  • Hwang YC & al.
  • Diabetes Metab J
  • 16 Jan 2019

  • curated by Sarfaroj Khan
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

According to a study published in the Diabetes & Metabolism Journal, 6 weeks of daily combination therapy low-dose rosuvastatin/ezetimibe showed reduction in low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB) and apolipoprotein B/A1 (apoB/A1) ratio comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus (T2DM). Triglyceride and FFA reductions were greater with the combination therapy than with rosuvastatin monotherapy.

Researchers evaluated 36 patients with type 2 diabetes mellitus who were randomly assigned to receive either rosuvastatin monotherapy (20 mg/day; n=20) or rosuvastatin/ezetimibe combination therapy (5 mg/10 mg/day; n=16) for 6 weeks. They assessed the change in apoB/A1 ratio and lipid parameters from baseline to the end of the 6-week treatment.

After 6 weeks of treatment, LDL-C levels significantly decreased in both groups (rosuvastatin group, –94.3±15.4 mg/dL and rosuvastatin/ezetimibe group, 89.9±22.7 mg/dL) with no significant difference between the 2 groups (P=.54). Changes in apoB and apoB/A1 ratio did not differ in both the rosuvastatin and rosuvastatin/ezetimibe groups (–62.0±20.9 mg/dL and –0.44 [–0.56 to –0.34], respectively, and –66.8±21.6 mg/dL and –0.38 [–0.54 to –0.32], respectively) (P=.86 and P=.58, respectively). Reductions in triglycerides and free fatty acids were greater in the rosuvastatin/ezetimibe group (–49.5 mg/dL [interquartile range (IQR), –108.5 to –27.5] and –170.5 μEq/L [IQR, –353.0 to 0.8], respectively) vs the rosuvastatin group (–10.5 mg/dL [IQR, –37.5 to 29.5] and 0.0 μEq/L [IQR, –136.8 to 146.0, respectively] (P=.1 and P=.5, respectively). Both treatments were generally well tolerated and no significant liver or muscle enzyme elevations were noted.

Authors concluded, “Further studies are warranted to determine whether the low-intensity statin with ezetimibe combination therapy provides additional cardiovascular benefits over high-intensity statin monotherapy; hence, a cardiovascular outcome study is needed to confirm the clinical significance of our findings.”

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.